The market for immuno oncology assays is expected to reach USD 5.9 billion by 2024 from USD 2.9 billion in 2018, at a CAGR of 12.7% during the forecast period. The growth of this market is primarily driven by factors such as the increasing adoption of targeted therapy over traditional therapy and increasing demand for mAbs. However, the high cost of immunotherapy treatment and the high attrition rate in the product development cycle are the major factors that are expected to restrain the growth of this market during the forecast period. Based on products, the immuno-oncology assays market is segmented into consumables and software. The consumables segment dominated the market with the largest share in 2018; this segment is also expected to register the highest CAGR during the forecast period. The large share of this segment can be attributed to the availability of a wide range of reagents and kits, increasing use of reagents in different oncology therapeutic treatments, increasi...
Latest Healthcare Industry Updates and Trends.